Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
Many researchers believe cancer cell therapies called CAR-Ts could shift the treatment paradigm for patients with autoimmune disease. But three recently disclosed deaths in Novartis’ …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Novartis, Bristol Myers halt autoimmune CAR-T trials after deaths
Novartis halts clinical trials following patient deaths
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis suspende testes de medicamento para doenças autoimunes após morte de três pacientes
Novartis pauses trials of experimental cell therapy after three deaths - Health - The Jakarta Post
Pharmakonzern Novartis stoppt nach Todesfällen mehrere Studien
Novartis suspende testes clínicos de medicamento para doenças autoimunes após morte de três pacientes
Novartis pausa ensaios de terapia voltada a distúrbios autoimunes e neurológicos após três mortes
